The Intravenous Immunoglobulin (IVIG) market across the 7MM was valued at around USD 7,384 million in 2025 and is expected to ...

Argenx (ARGX) announced an update on their ongoing clinical study. Argenx is currently recruiting participants for a study titled ‘Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study’.

A well-known singer in North Texas returns to the stage next week for a night she thought may never happen. Lauren Moore was diagnosed with a disease earlier this year that took her independence and ...

After overcoming an illness, Relly Ladner is ready to run the New York City Marathon. She is one of the 26 runners part of the New York Road Runner’s “Team Inspire,” a group of athletes with “ the ...

In a heartbreaking segment, the show spotlights the plight of Phil, a man diagnosed with CIDP — an aggressive, end-stage form of Guillain-Barré Syndrome. Phil’s only lifeline is a biweekly infusion of ...

Joe Pearson III woke up in his apartment in Sicily on May 30 unable to feel his legs. "I can see them, but I can't feel them," he said. He had been working there as a contractor for the Navy since ...

Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune disease that can cause severe numbness, weakness and disability. In a recent interview hosted by Sanofi, Dr. Jeffrey ...

A new Guillain-Barré syndrome mimic that appeared to be triggered by mild infection emerged in children with biallelic RCC1 variants, a case series showed. One of the first cases was seen in a ...

We present a 12-year-old boy with acute onset sensorimotor neuropathy and membranous glomerulonephritis associated with contactin-1 antibodies. This prompted us to explore the clinical characteristics ...

LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on Monday, ...